Cargando…

Coronary Artery Calcium Score for Personalization of Antihypertensive Therapy: A Pooled Cohort Analysis

The 2017 American College of Cardiology/American Heart Association high blood pressure (BP) guidelines recommend risk assessment of atherosclerotic cardiovascular disease to inform hypertension treatment in adults with elevated BP or low-risk stage I hypertension. The use of coronary artery calcium...

Descripción completa

Detalles Bibliográficos
Autores principales: Parcha, Vibhu, Malla, Gargya, Kalra, Rajat, Li, Peng, Pandey, Ambarish, Nasir, Khurram, Arora, Garima, Arora, Pankaj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946744/
https://www.ncbi.nlm.nih.gov/pubmed/33641360
http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.16689
_version_ 1783663106536243200
author Parcha, Vibhu
Malla, Gargya
Kalra, Rajat
Li, Peng
Pandey, Ambarish
Nasir, Khurram
Arora, Garima
Arora, Pankaj
author_facet Parcha, Vibhu
Malla, Gargya
Kalra, Rajat
Li, Peng
Pandey, Ambarish
Nasir, Khurram
Arora, Garima
Arora, Pankaj
author_sort Parcha, Vibhu
collection PubMed
description The 2017 American College of Cardiology/American Heart Association high blood pressure (BP) guidelines recommend risk assessment of atherosclerotic cardiovascular disease to inform hypertension treatment in adults with elevated BP or low-risk stage I hypertension. The use of coronary artery calcium (CAC) score to guide hypertension therapy has not been adequately evaluated. Participants free of cardiovascular disease were pooled from Multi-Ethnic Study of Atherosclerosis, Coronary Artery Risk Development in Young Adults, and Jackson Heart Study. The risk for incident cardiovascular events (heart failure, stroke, coronary heart disease), by CAC status (CAC-0 or CAC>0) and BP treatment group was assessed using multivariable-adjusted Cox regression. The 10-year number needed to treat to prevent a single cardiovascular event was also estimated. This study included 6461 participants (median age 53 years; 53.3% women; 32.3% Black participants). Over a median follow-up of 8.5 years, 347 incident cardiovascular events occurred. Compared with those with normal BP, the risk of incident cardiovascular event was higher among those with elevated BP/low-risk stage I hypertension and CAC>0 (hazard ratio, 2.4 [95% CI, 1.7–3.4]) and high-risk stage I/stage II hypertension (BP, 140–160/80–100 mm Hg) with CAC>0 (hazard ratio, 2.9 [95% CI, 2.1–4.0]). A similar pattern was evident across racial subgroups and for individual study outcomes. Among those with CAC-0, the 10-year number needed to treat was 160 for elevated BP/low-risk stage I hypertension and 44 for high-risk stage I or stage II hypertension (BP, 140–160/80–100 mm Hg). Among those with CAC>0, the 10-year number needed to treat was 36 and 22, respectively. Utilization of the CAC score may guide the initiation of hypertension therapy and preventive approaches to personalize cardiovascular risk reduction among individuals where the current guidelines do not recommend treatment.
format Online
Article
Text
id pubmed-7946744
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-79467442021-03-18 Coronary Artery Calcium Score for Personalization of Antihypertensive Therapy: A Pooled Cohort Analysis Parcha, Vibhu Malla, Gargya Kalra, Rajat Li, Peng Pandey, Ambarish Nasir, Khurram Arora, Garima Arora, Pankaj Hypertension Original Articles The 2017 American College of Cardiology/American Heart Association high blood pressure (BP) guidelines recommend risk assessment of atherosclerotic cardiovascular disease to inform hypertension treatment in adults with elevated BP or low-risk stage I hypertension. The use of coronary artery calcium (CAC) score to guide hypertension therapy has not been adequately evaluated. Participants free of cardiovascular disease were pooled from Multi-Ethnic Study of Atherosclerosis, Coronary Artery Risk Development in Young Adults, and Jackson Heart Study. The risk for incident cardiovascular events (heart failure, stroke, coronary heart disease), by CAC status (CAC-0 or CAC>0) and BP treatment group was assessed using multivariable-adjusted Cox regression. The 10-year number needed to treat to prevent a single cardiovascular event was also estimated. This study included 6461 participants (median age 53 years; 53.3% women; 32.3% Black participants). Over a median follow-up of 8.5 years, 347 incident cardiovascular events occurred. Compared with those with normal BP, the risk of incident cardiovascular event was higher among those with elevated BP/low-risk stage I hypertension and CAC>0 (hazard ratio, 2.4 [95% CI, 1.7–3.4]) and high-risk stage I/stage II hypertension (BP, 140–160/80–100 mm Hg) with CAC>0 (hazard ratio, 2.9 [95% CI, 2.1–4.0]). A similar pattern was evident across racial subgroups and for individual study outcomes. Among those with CAC-0, the 10-year number needed to treat was 160 for elevated BP/low-risk stage I hypertension and 44 for high-risk stage I or stage II hypertension (BP, 140–160/80–100 mm Hg). Among those with CAC>0, the 10-year number needed to treat was 36 and 22, respectively. Utilization of the CAC score may guide the initiation of hypertension therapy and preventive approaches to personalize cardiovascular risk reduction among individuals where the current guidelines do not recommend treatment. Lippincott Williams & Wilkins 2021-03-01 2021-04 /pmc/articles/PMC7946744/ /pubmed/33641360 http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.16689 Text en © 2021 The Authors. Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made. This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
spellingShingle Original Articles
Parcha, Vibhu
Malla, Gargya
Kalra, Rajat
Li, Peng
Pandey, Ambarish
Nasir, Khurram
Arora, Garima
Arora, Pankaj
Coronary Artery Calcium Score for Personalization of Antihypertensive Therapy: A Pooled Cohort Analysis
title Coronary Artery Calcium Score for Personalization of Antihypertensive Therapy: A Pooled Cohort Analysis
title_full Coronary Artery Calcium Score for Personalization of Antihypertensive Therapy: A Pooled Cohort Analysis
title_fullStr Coronary Artery Calcium Score for Personalization of Antihypertensive Therapy: A Pooled Cohort Analysis
title_full_unstemmed Coronary Artery Calcium Score for Personalization of Antihypertensive Therapy: A Pooled Cohort Analysis
title_short Coronary Artery Calcium Score for Personalization of Antihypertensive Therapy: A Pooled Cohort Analysis
title_sort coronary artery calcium score for personalization of antihypertensive therapy: a pooled cohort analysis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946744/
https://www.ncbi.nlm.nih.gov/pubmed/33641360
http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.16689
work_keys_str_mv AT parchavibhu coronaryarterycalciumscoreforpersonalizationofantihypertensivetherapyapooledcohortanalysis
AT mallagargya coronaryarterycalciumscoreforpersonalizationofantihypertensivetherapyapooledcohortanalysis
AT kalrarajat coronaryarterycalciumscoreforpersonalizationofantihypertensivetherapyapooledcohortanalysis
AT lipeng coronaryarterycalciumscoreforpersonalizationofantihypertensivetherapyapooledcohortanalysis
AT pandeyambarish coronaryarterycalciumscoreforpersonalizationofantihypertensivetherapyapooledcohortanalysis
AT nasirkhurram coronaryarterycalciumscoreforpersonalizationofantihypertensivetherapyapooledcohortanalysis
AT aroragarima coronaryarterycalciumscoreforpersonalizationofantihypertensivetherapyapooledcohortanalysis
AT arorapankaj coronaryarterycalciumscoreforpersonalizationofantihypertensivetherapyapooledcohortanalysis